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A randomized controlled trial was conducted to assess the eﬃcacy of an individually administered form of cognitive behavioral
treatment for ﬁbromyalgia. In an additive design, 76 patients diagnosed with ﬁbromyalgia were randomly assigned to either the
experimental treatment (aﬀective-cognitive behavioral therapy, 10 individual sessions, one per week) administered concurrently
withtreatment-as-usualorto anunaugmented treatment-as-usualcondition.Statisticalanalysisconducted attheendoftreatment
(3 months after the baseline assessment) and at a followup (9 months after the baseline assessment) indicated that the patients
receiving theexperimental treatment reported lesspain andoverall better functioning thancontrol patients, both at posttreatment
and at followup. The implications of these ﬁndings for future research are discussed.
1.Introduction
Fibromyalgia (FM) is a prevalent and disabling syndrome.
It is characterized by widespread musculoskeletal pain, mul-
tiple tender points, sleep disturbance, fatigue, and stiﬀness
[1, 2]. The prevalence of FM has been estimated to be
about 2% of the population [2]. Patients meeting criteria
for FM have been shown to overuse health care services and
experience high rates of disability [3–5].
At present, FM appears to be extremely challenging to
treat [6]. Although some pharmacological and nonpharma-
cological treatments have produced moderate beneﬁts, no
intervention has yet been demonstrated capable of generat-
ing clinically signiﬁcant improvement in the majority of FM
patients [6]. The controlled clinical trial literature suggests
that pharmacological agents provide some relief to FM
patients, though the magnitude of these eﬀects is modest
[7, 8]. Psychosocial interventions also have shown some
promiseinalleviating FMsymptoms, with exerciseprograms
and cognitive-behavioral treatments appearing most potent
[8, 9]. Notwithstanding, empirical reviews of the eﬃcacy of
cognitive-behavioral treatment (CBT) for FM have revealed
mixed results, some showing low-to-medium eﬀect sizes
[9, 10], others showing no eﬀect [11]. Because, to date, CBT
for FM has been administered in groups, the eﬃcacy of
individually administered CBT for FM has not been assessed
within a controlled experimental design. We hypothesized
that an individually administered, intensive, and individu-
alized CBT treatment would achieve more powerful eﬀects
than previous group-administered CBT.
We developed an individually administered (CBT) for
FM that includes relaxation training, activity regulation, fa-
cilitation of emotional awareness, cognitive restructuring,
and interpersonal communication training. The elicitation
and exploration of aﬀect is an approach rarely used in CBT
[12].W e,however ,havefoundthiscomponenttobeapower -
ful clinical tool with patients who cannot or do not willingly
access and experience emotion, indeed so powerful that
we have sometimes labeled our approach aﬀective-cognitive
behavioral therapy (ACBT) [13]. In this investigation, we2 Pain Research and Treatment
hypothesized that ACBT would reduce pain intensity and
improve other symptomatology overand above the eﬀectsof
treatment as usual in patients with FM.
2.Materialsand Methods
2.1. Study Design. We conducted a randomized, controlled
treatment trial, using an additive design [14], in which pa-
tients diagnosed with FM received 1 of 2 treatments: (1) 10
weekly sessions of individually administered ACBT in addi-
tion to treatment-as-usual (TAU) or (2) TAU alone. Partic-
ipants were assessed three times during the course of the
study: at baseline, 3 months after baseline (posttreatment),
and 9 months after baseline (followup).
2.2.StudyPopulationand Settings. Participants were referred
to the study by their treating rheumatologists. Men and
women, ages 18 to 70, who met ACR criteria for FM, as diag-
nosed by their rheumatologists and conﬁrmed by a medical
history review, were eligible for the study. Individuals
manifesting any of the following were excluded from the
study: pain from traumatic injury or structural or regional
rheumatic disease, rheumatoid arthritis, inﬂammatory ar-
thritis, autoimmune disease, unstable medical or psychiatric
illness, activesuicidalideation,ahistory ofpsychosis, current
psychoactive substance dependence, or a medication regi-
men that had not been stable for at least 2 months prior to
baseline. Women who were pregnant or attempting to con-
ceive also were excludedfrom the study. Participation in psy-
chotherapy concurrent with the period between the baseline
and posttreatment appointment, which occurred 3 months
after baseline, was not permitted.
The study took place in an academic medical clinic at
Robert Wood Johnson Medical School (RWJMS). The study
was approved by RWJMS’s institutional review board. Writ-
ten informed consent was obtained from all participants.
2.3. Treatment Conditions. The ACBT is a 10-session, indi-
vidually-administered, manualized interventiondesignedfor
patients with functional somatic symptoms. The treatment,
which we developed, is described in detail elsewhere [13].
The treatment manual allows for adaptation and adjustment
tothe individualpatternof symptoms and life situations pre-
sented by the patients.
2.4. Randomization and Masking. Participants were ran-
domly assigned to ACBT + TAU or TAU using a computer-
generated random number sequence. Neither blocking nor
stratiﬁcation was used. Study personnel administering ques-
tionnaires were masked to participants’ treatment condition.
2.5.Initial Assessment. Participants were assessed at baseline,
just before treatment began. Demographic characteristics
and baseline levels of the outcome measures (described
below) were assessed. The Hollingshead four-factor in-
dex was employed to measure participants’ socioeconomic
status [15]. It is a widely used measure calculated from
an individual’s (and his/her working spouse’s, if applicable)
educational background and occupational history.
2.6. Outcome Measures. The primary outcome measure was
a 10cm visual analog scale of pain (VAS) anchored at its
lowest point by the expression “no pain” and at its highest
point by the phrase “very severe pain.” Participants were
asked to rate their level of pain over the preceding seven
days. The VAS has been used widely in FM clinical trials to
measure pain severity and appears to be sensitive to change
[16].
Secondary measures included the Medical Outcomes
Study (MOS) SF-36 Physical Functioning Scale (MOS-PF),
the Chronic Pain Self-Eﬃcacy Scale (CPSE), the Beck De-
pression Inventory (BDI), and the Beck Anxiety Inventory
(BAI). Physical functioning was assessed with the physical
functioning subscale oftheMOSSF-36,a 36-itemself-report
questionnaire assessing various aspects of quality of life. The
MOS SF-36 has been validated across a wide range of con-
ditions including ﬁbromyalgia [17, 18]. Self-eﬃcacy for pain
management was assessed with the pain management sub-
scale of the Chronic Pain Self-Eﬃcacy Scale (CPSE) [19].
Current level of depression was assessed with the Beck
Depression Inventory (BDI), a 21-item self-report question-
naire measuring various aspects of depression. The BDI has
been used widely in the depression and ﬁbromyalgia liter-
atures and is considered psychometrically sound [20, 21].
Current level of anxiety was measured with the Beck Anxiety
Inventory (BAI). The BAI is a 21-item self-report scale
assessing the aﬀective, cognitive, and physical symptoms of
anxiety which has demonstrated sound psychometric pro-
perties [22, 23].
Because patients’ expectations for treatment outcome
may be associated with response to treatment [24], theywere
assessed with the Expectation Rating Scale [25]. The Expec-
tation Rating Scale is made up of three statements to which
patients respond by placing a mark on a 10cm VAS [25].
2.7. Statistical Analysis. Diﬀerencesbetween groups onbase-
line characteristics were tested using unpaired t-tests for
continuous variables or χ2 tests for categorical variables. An
intent-to-treat approach, based on data from all randomized
participants, was used in all analyses. The treatment condi-
tion (ACBT + TAU or TAU) served as the independent vari-
able contrast in all analyses, in what is typically referred to as
an additive design, in which both levels of the independent
variable possess a commonelementto which, in one group,a
putativelytherapeuticagentisadded[14].Groupswerecom-
paredontheprimary andsecondaryoutcomevariablesatthe
posttreatment andatfollow-up appointments, 3monthsand
9 months after baseline, respectively. In all, 12 participants
were lost to attrition (see Figure 1). Missing data were
imputed via the last observation carried forward method.
Bonferroni’s correction was used to control for the eﬀect of
multiple comparisons on overall experiment-wise error rate,
which was set as P<. 05. All tests of statistical signiﬁcance
were 2-tailed, and all statistical analyses were performed
using SAS, version 8 (SAS Institute Inc, Cary, NC).Pain Research and Treatment 3
87 screened in person
5 declined to participate
6 ineligible
76 randomized
38 assigned to ACBT + TAU 38 assigned to TAU
35 completed 3-mo (posttreatment) assessment
3 withdrew from study
38 included in primary analysis
34 completed 3-mo (posttreatment) assessment
4 withdrew from study
38 included in primary analyses
32 completed 9-mo (followup) assessment
3w i t h d r e wf r o ms t u d y
32 completed 9-mo (followup) assessment
2 withdrew from study
Figure 1: Flow of participants through the study.
3.Results
There were no signiﬁcant diﬀerences on any baseline char-
acteristics between the two treatment groups (Table 1), sug-
gesting that outcome ﬁndings related to treatment were not
confounded by any demographic variable. Most participants
were middle-aged women who had experienced widespread
pain for an average of 11.5 years.
A one-way analysis of covariance with one ﬁxed eﬀect
(ACBT+TAUversusTAU),using baseline scoresasthecova-
riate,wasconductedontheprimary outcomemeasure (VAS)
at posttreatment. The main eﬀect for treatment was highly
signiﬁcant, F(1,73) = 45.94, P<. 0001, Hedges’s g = 0.90,
with patients receiving ACBT + TAU indicating less pain
thanthosereceiving TAU.Atfollowupthediﬀerencebetween
treatment conditions continued to be highly signiﬁcant,
F(1,73) = 52.83,P<. 0001,Hedges’sg = 0.95(seeFigure 2).
Thedataw er eals oe xaminedf r omthepers pecti v eofclin-
ical signiﬁcance, using the criterion of 30% improvement.
At posttreatment 25 patients (65.8% of the intent-to-treat
sample) in the ACBT + TAU group, showed at least 30%
improvement from baseline on the VAS, whereas only 2 pa-
tients (5.2%) in the TAU group improved by 30%. At
followup24patientsintheACBT+TAUgroup(63.2%)were
at least 30% improved from baseline on the VAS, whereas
onlyoneassessed patient(2.6%)intheTAUgroupcontinued
to be improved by 30%.
In Table 2, a summary is presented of all analyses of pri-
mary andsecondarydependentvariables.Theoverallpattern
of results shows a relatively strong eﬀect for the ACBT upon
pain in FM, an eﬀect that continues at followup. Signiﬁcant
but weaker eﬀects were discovered for all the secondary
targets at posttreatment, but a Bonferroni correction would
have rendered the eﬀect on the CPSE pain management scale
lessthansigniﬁcantatfollowup,whencorrectingformultiple
comparisons (see Figures 3 and 4).
4.Discussion
Our ﬁndings suggest that an intensive individually-admin-
istered ACBT produces signiﬁcant improvement in self-re-
ported pain in FM. The treatment’s impact on self-reported
physical functioning, self-eﬃcacy, depression, and anxiety
was statistically signiﬁcant but smaller. Our data are consis-
tent with recent reviews that have found CBT to be perhaps
the most eﬀective psychosocial treatment for FM [9]. The
eﬀect size found for ACBT on VAS pain severity was both
large and durable compared to those reported in other
studiesexamining CBT,although ﬁndings on the otherstudy
variables were more or less in line with results of earlier
research. The VASisoftenconsideredto be theinstrument of
choice in studying treatment of FM patients [16], although
there is enough variability in the way the VAS is presented
to study patients, for example, diﬀering anchor points, that
comparisonsacross studiesare renderedsomewhat problem-
atic.Ifwe simply lookwithin ourown sample nonparametri-
cally, using a 30% improvement on the VAS as the criterion,4 Pain Research and Treatment
Table 1: Baseline characteristics of the participants∗.
ACBT + TAU TAU P value
n = 38 n = 38
Age, mean (SD), y 47.79 (9.28) 50.21 (10.14) n.s.
Female, no. (%) 34 (89.47) 33 (86.84) n.s.
Race/ethnicity, no. (%)
White 30 (78.95) 28 (73.68)
n.s. African american 2 (5.26) 0 (0.00)
Hispanic 3 (7.89) 6 (15.79)
Other 3 (7.89) 4 (10.53)
Education, no. (%)
Graduate degree 10 (26.32) 6 (15.79)
n.s. College degree 10 (26.32) 12 (31.58)
Some college 9 (23.68) 13 (34.21)
High school or less 9 (23.68) 7 (18.42)
Married, no. (%) 19 (50.00) 21 (55.26) n.s.
Employed, no. (%) 16 (42.11) 21 (55.26) n.s.
Hollingshead SES, mean
(SD) 47.51 (10.20) 49.61 (9.61) n.s.
Expectation Rating Scale,
mean (SD) 17.20 (5.21) 16.09 (6.86) n.s
ACBT indicates aﬀective cognitive behavioral therapy, TAU indicates treat-
ment as usual, Hollingshead SES indicates Hollingshead socioeconomic
status scale score.
∗Data are presented as No. (%) unless otherwise indicated.
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Figure 2: Mean and standard error of the mean of the Visual
Analogue Scale (VAS) for pain severity TAU indicates treatment as
usual. ACBT indicates aﬀective cognitive-behavioral treatment.
theACBTaugmentationofTAUis clinicallyquitesigniﬁcant,
given that TAU was almost entirely without beneﬁt in our
sample. Severalotherstudiesoftreatment forFMhavefound
TAU to yield no clinically signiﬁcant improvement [26, 27].
Given the structure of the experimental design, however,
we cannot infer with certainty that factors unique to ACBT
were causal elements in the observed changes or that ACBT
0
10
20
30
40
50
60
70
Baseline Posttreatment
TAU
A C B T+T A U
M
O
S
-
p
h
y
s
i
c
a
l
f
u
n
c
t
i
o
n
i
n
g
Followup
Figure 3: Mean and standard error of the mean of the MOS-
physical functioning scale TAU indicates treatment as usual. ACBT
indicates aﬀective cognitive-behavioral treatment.
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Figure 4: Mean and standard error of the mean of the self-eﬃcacy
forpainmanagementscale.TAUindicatestreatmentasusual.ACBT
indicates aﬀective cognitive-behavioral treatment.
administered without TAU would be an eﬀective treatment.
What we observed was the successful augmentation of TAU
by ACBT. Given that generally, and especially in our study,
TAU is not an eﬃcacious treatment for FM, our ﬁndings
suggest that future research should examine the potential
utility of treatments such as the one evaluated here. One
questionthatcouldbeaddressed iswhetheradditionalACBT
sessions, either in the form of an extended treatment or
“booster sessions” occurring in the months following the
initial intervention, would yield greater therapeutic impact.
There are a variety of reasons why ACBT may have been
especially beneﬁcial to our patients. Because each of our pa-
tientsreceived10individualsessions withthesame therapist,
perhaps a somewhat stronger bond may have developed
between patient and therapist than is often seen in group-
administered CBT. The use of extensive relaxation trainingPain Research and Treatment 5
Table 2: Summary of outcomes.
Outcomes FP Hedges’ g
Visual analogue scale for pain severity Posttreatment 45.94 <.0001 0.90
Followup 52.83 <.0001 0.95
MOS SF-36 physical functioning Posttreatment 13.25 <.0005 0.35
Followup 9.89 <.0024 0.28
Self-eﬃcacy for pain management Posttreatment 10.42 <.0019 0.65
Followup 4.13 <.0459 0.40
Beck depression inventory Posttreatment 11.03 <.001 0.56
Followup 15.70 <.0002 0.60
Beck anxiety inventory Posttreatment 11.79 <.001 0.45
Followup 12.04 <.0009 0.62
and exploration of emotions gives our treatment [13]s o m e
of the ambience of standard psychotherapy as it is practiced
in the generic clinical arena, rather than the somewhat
psychoeducational feeling that group-administered CBT can
sometimes possess. Whether relationship factors per se
added to the therapeutic power or simply inclined partici-
pants to indicate more symptom relief is impossible to say
butraises questions that could be systematically examined in
subsequent research. The failure to ﬁnd higher expectations
for treatment among ACBT + TAU patients suggests that the
treatment eﬀect was not due to mechanisms implicated in
the response to placebos.
The durability of our treatment eﬀect upon pain may
have had to do with the more intensive, individualized treat-
ment that individually administered sessions can provide.
The very use of relaxation training throughout treatment
and the strong emphasis given to it as a valuable stress
management skill that should be regularly applied in one’s
life and be a permanent part of one’s coping repertory may
give our patients a tool that is eﬀective in reducing the
discomfort associated with FM. Whether the component
of our treatment that places patients in closer touch with
emotions that are often suppressed or denied is a factor in
treatment eﬃcacy is a question to be answered in future
research. From a practical clinical standpoint, it would
appear that our approach to cognitive behavioral therapy,
ACBT, can be individually administered to FM patients with
some likelihood of improving their symptoms.
5.Conclusion
An individually administered aﬀective-cognitive behavioral
treatment resulted in sustained improvement in pain and
relatedsymptomatologyinasampleofpatientswithFMwho
had been referred for treatment by their rheumatologists.
Additional research is needed to replicate our ﬁndings and
to explore some questions raised. Is intensive, individually
administered CBT a more powerful treatment for FM than
treatmentprovidedinpatientgroups?Arethefactorsthatare
stressed in our treatment, creating high competence in relax-
ation methods and emphasizing the patient’s emotional self-
awareness, important to success in the psychosocial treat-
ment of FM?
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